Cancer Family
Reproductive System Neoplasm
CI-CAN-00000338Explore in graph →
Non-malignant3,041 active trials38 approved drugs197 evidence items
- NCIt
- C3674
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000338Explore in graph →
Clinical trials
13,668 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06235697 | Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment(ASCENDE-SBRT) | recruiting | Phase 3 | 710 | Canadian Cancer Trials GroupNETWORK | 2 | Apr 14, 2026 | clinicaltrials |
| NCT04787744 | Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer(VA STARPORT) | recruiting | Phase 2 / Phase 3 | 464 | VA Office of Research and DevelopmentFED |
| 1 |
| Apr 8, 2026 |
| clinicaltrials |
| NCT07418749 | A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer | recruiting | Phase 3 | 398 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Apr 6, 2026 | clinicaltrials |
| NCT02064673 | Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy | recruiting | Phase 3 | 650 | yair lotanOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT07500701 | Salvage Moderate Hypofractionated Versus Ultrahypofractionated Radiotherapy for Biochemical Recurrence After Radical Prostatectomy in Prostate Cancer | recruiting | Phase 3 | 270 | Samsung Medical CenterOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT03594760 | PSMA-PET: Deep Radiomic Biomarkers of Progression and Response Prediction in Prostate Cancer | recruiting | Phase 3 | 1,000 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT06282588 | Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers(THUNDER) | recruiting | Phase 2 / Phase 3 | 493 | Cancer Research AntwerpOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT07472140 | PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer | recruiting | Phase 2 / Phase 3 | 120 | N.N. Alexandrov National Cancer CentreOTHER_GOV | 1 | Mar 16, 2026 | clinicaltrials |
| NCT07319429 | Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification(FEMUS) | recruiting | Phase 2 / Phase 3 | 260 | Fudan UniversityOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT03495427 | PSMA-PET Imaging for Detecting Early Metastatic Prostate Cancer in Men w/ High Decipher Test Scores | recruiting | Phase 2 / Phase 3 | 60 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT06650579 | REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial | recruiting | Phase 3 | 72 | Emory UniversityOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT06513065 | Study to Evaluate the Non-inferiority of Low-dose HIPEC Versus High-dose HIPEC in the Treatment of PMP (HIPEC-PMP)(HIPEC-PMP) | recruiting | Phase 3 | 176 | University of SouthamptonOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT05827523 | Interval Cytoreductive Surgery With or Without HIPEC for Ovarian Cancer (FOCUS / KOV-HIPEC-04)(FOCUS / KOV-04) | recruiting | Phase 3 | 520 | National Cancer Center, KoreaOTHER_GOV | 1 | Feb 13, 2026 | clinicaltrials |
| NCT06593665 | Intrathecal Morphine Versus Intravenous Methadone for Postoperative Analgesia Following Retroperitoneal Lymph Node Dissection.(RPLND) | recruiting | Phase 3 | 142 | Indiana UniversityOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT06563388 | Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial(ID-COMET) | recruiting | Phase 3 | 800 | Roswell Park Cancer InstituteOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT06671548 | Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids | recruiting | Phase 3 | 120 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Feb 2, 2026 | clinicaltrials |
| NCT06712472 | Randomized Phase III Trial Testing Maintenance Olaparib Versus Observation After Adjuvant Chemoradiation for p53abn Endometrial Cancer(RAINBO-RED) | recruiting | Phase 3 | 554 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT05838716 | Vitamin D for Prostate Endocrine Therapy(ViPER) | recruiting | Phase 3 | 240 | University of RochesterOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT07298642 | Extended-field Proton Therapy for Cervical Cancer | recruiting | Phase 2 / Phase 3 | 44 | National Taiwan University HospitalOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT06963268 | Validation of the Sentinel Lymph Node Technique in Early-stage Ovarian Cancer (SENTOV II)(SENTOV II) | recruiting | Phase 3 | 200 | Instituto de Investigacion Sanitaria La FeOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT07293585 | Vascular Optimized Radiotherapy Tuned to Critical Structures for Erectile Function Using High-Precision X-Ray Treatment(VORTEX) | recruiting | Phase 3 | 200 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT03701581 | 4-aminopyridine Treatment for Nerve Injury | recruiting | Phase 2 / Phase 3 | 70 | John ElfarOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT06855069 | HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer | recruiting | Phase 3 | 468 | Hansoh BioMedical R&D CompanyINDUSTRY | 1 | Dec 17, 2025 | clinicaltrials |
| NCT03422198 | Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer(SAVE) | recruiting | Phase 3 | 188 | University of UtahOTHER | 1 | Dec 12, 2025 | clinicaltrials |
| NCT07260435 | Apa/Enza-short Study: Shorter Treatment With Androgen Receptor Pathway Inhibitor in Patients With Low-volume Metastatic Castration-sensitive Prostate Cancer(Apa/Enza-short) | recruiting | Phase 3 | 400 | Nick BeijeOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT05786716 | DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT05768178 | DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT05770102 | DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT06817161 | Benefit of Transcutaneous Auricular Vagus Nerve Stimulation in Improving Quality of Life in First Line Treatment of Ovarian Cancer:(ESTANVO) | recruiting | Phase 3 | 116 | Centre Francois BaclesseOTHER | 1 | Oct 7, 2025 | clinicaltrials |
| NCT07209878 | 68Ga-PSMA-11 PET Imaging for Diagnosing Prostate Cancer, a Head-to-head Comparison With mpMRI | recruiting | Phase 2 / Phase 3 | 100 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Oct 7, 2025 | clinicaltrials |
| NCT07166042 | Guided Meditation During Radiation Therapy for Breast and Gynecological Malignancies(Med-RT BG) | recruiting | Phase 3 | 34 | University of UtahOTHER | 1 | Oct 3, 2025 | clinicaltrials |
| NCT04111978 | MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)(MATAO) | recruiting | Phase 3 | 540 | Swiss GO Trial GroupNETWORK | 3 | Sep 29, 2025 | clinicaltrials |
| NCT05974774 | Intermittent Androgen Deprivation Therapy in the Era of AR Pathway Inhibitors | recruiting | Phase 3 | 1,600 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 3 | Sep 19, 2025 | clinicaltrials |
| NCT03678025 | Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer | recruiting | Phase 3 | 1,273 | SWOG Cancer Research NetworkNETWORK | 5 | Sep 11, 2025 | clinicaltrials |
| NCT05009082 | Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer | recruiting | Phase 3 | 970 | AGO Study GroupOTHER | 1 | Sep 10, 2025 | clinicaltrials |
| NCT05862272 | A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis | recruiting | Phase 3 | 1,000 | Sumitomo Pharma Switzerland GmbHINDUSTRY | 1 | Aug 6, 2025 | clinicaltrials |
| NCT05796973 | Measuring Oncological Value of Exercise and Statin(MOVES) | recruiting | Phase 3 | 240 | Tampere University HospitalOTHER | 1 | Jun 27, 2025 | clinicaltrials |
| NCT06954584 | Fluzoparib+Bevacizumab/Dietary Intervention vs Fluzoparib Monotherapy as First-line Maintenance in HRD+/- Advanced Ovarian Cancer | recruiting | Phase 3 | 424 | Tongji HospitalOTHER | 1 | Jun 24, 2025 | clinicaltrials |
| NCT06156514 | Evaluation of Concomitant Chemo-radiotherapy With Cisplatine vs Gemcitabin in Locally Advanced Cervicouterine Cancer(MICHELE) | recruiting | Phase 3 | 140 | National Institute of CancerologíaOTHER_GOV | 1 | May 28, 2025 | clinicaltrials |
| NCT03201861 | Addition of Cisplatin to Adjuvant Chemotherapy for Early Stage Breast Cancer in High-Risk Women | recruiting | Phase 3 | 762 | RenJi HospitalOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT06459687 | Phase III Study of Socazolimab as First-Line Treatment in Persistent, Recurrent, or Metastatic Cervical Cancer | recruiting | Phase 3 | 440 | Lee's Pharmaceutical LimitedINDUSTRY | 1 | May 14, 2025 | clinicaltrials |
| NCT04833426 | Impact of Peri-operative tEstosterone Levels on oNcological and Functional Outcomes in RadiCal prostatEctomy(ENFORCE) | recruiting | Phase 3 | 140 | Canisius-Wilhelmina HospitalOTHER | 1 | May 2, 2025 | clinicaltrials |
| NCT05407987 | Ferric Derisomaltose and Outcomes in the Recovery of Gynecologic Oncology: ERAS (Enhanced Recovery After Surgery)(FORGE II) | recruiting | Phase 3 | 82 | AHS Cancer Control AlbertaOTHER | 1 | Apr 25, 2025 | clinicaltrials |
| NCT06945315 | SAFE Nerve Sparing Guided by Micro-ultrasound (MUS) | recruiting | Phase 3 | 196 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Apr 25, 2025 | clinicaltrials |
| NCT03903835 | ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer(ProBio) | recruiting | Phase 3 | 750 | Karolinska InstitutetOTHER | 4 | Apr 9, 2025 | clinicaltrials |
| NCT04794777 | Comparing "Salvage" Radiotherapy and Individualized PSMA PET/CT Targeted Treatment in With Relapsing Prostate Cancer | recruiting | Phase 3 | 450 | Stefan CarlssonOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT05169112 | Impact of Hormonal Therapy on Prostate Cancer Recurrence After Radical Prostatectomy | recruiting | Phase 3 | 72 | Ottawa Hospital Research InstituteOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT06641635 | Moderated Hypofractionated Online Adaptive Radiotherapy in Cervical Cancer | recruiting | Phase 3 | 440 | Peking Union Medical College HospitalOTHER | 1 | Mar 18, 2025 | clinicaltrials |
| NCT06565247 | Evaluation of PSMA-PET and mpMRI in High-risk Prostate Cancer - Using Histopathologic Validation | recruiting | Phase 3 | 60 | Region VästerbottenOTHER_GOV | 1 | Mar 4, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Apr 14, 2026source: clinicaltrials